News & Events
Insight Genetics today announced the launch of Insight Molecular Labs. This CLIA-certified laboratory offers diagnostic tests that identify specific cancer biomarkers. It provides clinical trial support services for targeted therapeutics, assisting in the identification of appropriate patients for trials, and specializes in the detection and monitoring of drug resistance in patients being treated with specific cancer therapies.
Insight Genetics partnered with the University of Colorado and Morris Laboratories in Memphis, Tenn., to present new data on alternative testing methods that identify atypical patterns of ALK mutation in non-small cell lung cancer patients at the Association for Molecular Pathology (AMP) Annual Meeting.
Insight Genetics Inks Deal with St. Jude Children’s Research Hospital to Improve Donor Matching in Bone Marrow Transplants
Insight Genetics today announced it has entered into an exclusive, worldwide licensing agreement with St. Jude Children’s Research Hospital for a genetic test known as the KIR/KIR-Ligand Assay. The test helps to predict the success of bone marrow transplants by identifying the optimal bone marrow donor subtype. Use of the KIR/KIR-Ligand Assay has been shown to prevent the return of cancer in transplant recipients and reduce risk of death following bone marrow transplantation by about 60 percent. As part of the agreement, Insight Genetics will optimize the KIR/KIR-Ligand Assay for rapid, high-capacity use and make it broadly available to physicians and their patients as well as donor registries.
Insight Genetics Awarded National Cancer Institute Contract to Advance Lung Cancer Diagnosis and Treatment
Insight Genetics, Inc. today announced it has received a Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) to continue its development of a diagnostic test that meets the significant unmet need for the diagnosis and treatment of non-small cell lung cancer (NSCLC). A continuation of work that Insight Genetics began with the NCI in 2012, the $1,499,412 Fast-Track contract will advance the development of a panel of assays designed to provide a fast and accurate way to identify and characterize genetic mutations associated with non-small cell lung cancer.
Insight Genetics today announced that it has added four new team members: David Burg is Associate Director, Business Development; Dan Bailey, MBA, is Senior Associate, New Product Planning; Tyler Nielsen, MBS, is Research Associate III; Lindsay Chatfield is Research Associate I